NEW YORK (GenomeWeb News) – Irish drug development services firm Icon said this week that it has signed an agreement with Empire Genomics to provide personalized medicine development services.
The firms will combine Empire's expertise in pharmacogenomics and computational modeling of disease states with Icon's translational medicine capabilities, clinical trial design, and expertise in biomarkers. They said the partnership will enable the identification of populations that respond to targeted drugs, permit stratification of patients through the development and use of companion diagnostics, and streamline drug development programs.
Financial and other terms of the alliance were not disclosed.
Buffalo, NY-based Empire Genomics was founded in 2006 using research started at the Roswell Park Cancer Institute. The firm makes array-based research products, Bacterial Artificial Chromosome libraries, and FISH probes.